PubRank

M B Khazaeli

Author PubWeight™ 71.14‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A 1989 2.15
2 Localization of iodine-125-mIP-Des-Met14-bombesin (7-13)NH2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer. J Nucl Med 1997 2.05
3 Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001 1.87
4 Use of chlorotoxin for targeting of primary brain tumors. Cancer Res 1998 1.59
5 Blood volume redistribution during cross-clamping of the descending aorta. Anesth Analg 1994 1.52
6 Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med 1992 1.49
7 Cadmium-binding component in Escherichia coli during accommodation to low levels of this ion. Appl Environ Microbiol 1981 1.49
8 Expression of human endogenous retrovirus k envelope transcripts in human breast cancer. Clin Cancer Res 2001 1.38
9 Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol 2006 1.37
10 Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res 1999 1.15
11 A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 2002 1.14
12 Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 1992 1.12
13 Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol 1997 1.10
14 A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 2003 1.09
15 A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 2001 1.06
16 Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med 1996 1.05
17 Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas 1992 1.05
18 Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J Nucl Med 2005 1.00
19 Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen. J Immunol 1987 0.98
20 Monitoring method for surface contamination caused by selected antineoplastic agents. Am J Health Syst Pharm 2002 0.96
21 Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma. Hum Pathol 2003 0.94
22 Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses. J Natl Cancer Inst 1988 0.93
23 Radiation dosimetry of 131I-chlorotoxin for targeted radiotherapy in glioma-bearing mice. J Neurooncol 2005 0.92
24 Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome. Crit Care Med 1990 0.91
25 Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994 0.91
26 Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjug Chem 2003 0.90
27 Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes. J Med Chem 1999 0.89
28 Improved synthesis of the bifunctional chelating agent 1,4,7,10-tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N',N'',N'''-tri s(acetic acid)cyclododecane (PA-DOTA). Bioorg Med Chem 1999 0.89
29 Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother Radiopharm 2001 0.89
30 Targeting strategies for cancer radiotherapy. Clin Cancer Res 1999 0.87
31 Development of an HPLC method for simultaneous analysis of five antineoplastic agents. Appl Occup Environ Hyg 2003 0.87
32 Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects. J Natl Cancer Inst 1988 0.87
33 Pilot study using a humanized CC49 monoclonal antibody (HuCC49DeltaCH2) to localize recurrent colorectal carcinoma. Ann Surg Oncol 2004 0.85
34 Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Cancer Res 1996 0.84
35 Phase I clinical trial of CO17-1A monoclonal antibody. Hybridoma 1986 0.84
36 Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49. Cancer Res 1995 0.84
37 A new monitoring method using solid sorbent media for evaluation of airborne cyclophosphamide and other antineoplastic agents. Appl Occup Environ Hyg 2003 0.84
38 Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration. J Immunother Emphasis Tumor Immunol 1995 0.83
39 Idiotypic vaccination with a murine anti-dsDNA antibody: phase I study in patients with nonactive systemic lupus erythematosus with nephritis. J Rheumatol 1999 0.83
40 A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer. Cancer Res 1993 0.83
41 Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene. Gene Ther 1996 0.83
42 Growth-inhibitory effects of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin on human malignant cell lines in vitro. J Cancer Res Clin Oncol 1994 0.83
43 Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein. Cancer Biother Radiopharm 2005 0.82
44 Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res 1999 0.82
45 Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy. J Nucl Med 2002 0.81
46 Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration. Cancer Biother Radiopharm 2005 0.81
47 Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res 1995 0.81
48 Production of a single chain anti-CEA antibody from the hybridoma cell line T84.66 using a modified colony-lift selection procedure to detect antigen-positive ScFv bacterial clones. Hybridoma 1998 0.81
49 An advanced solid support for immunoassays and other affinity applications. Biotechniques 1993 0.80
50 Radioimmunoassay of free beta-subunit of human chorionic gonadotropin as a prognostic test for persistent trophoblastic disease in molar pregnancy. Am J Obstet Gynecol 1986 0.80
51 Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphasis Tumor Immunol 1996 0.80
52 Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. J Nucl Med 1995 0.80
53 Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein. Clin Cancer Res 2005 0.79
54 Evaluation of human anti-mouse antibody response in normal volunteers following repeated injections of fanolesomab (NeutroSpec), a murine anti-CD15 IgM monoclonal antibody for imaging infection. Nucl Med Commun 2004 0.79
55 Approaches to enhance cancer radiotherapy employing gene transfer methods. Gene Ther 1996 0.79
56 Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure. Bioconjug Chem 2004 0.79
57 A phase II trial of murine monoclonal antibody 17-1A and interferon-gamma: clinical and immunological data. Cancer Immunol Immunother 1990 0.79
58 Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. J Immunol 1993 0.78
59 Synthesis of bombesin analogues for radiolabeling with rhenium-188. Cancer 1997 0.78
60 Direct quantitation of IgG subclasses 1, 2, and 3 bound to red cells by Rh1 (D) antibodies. Transfusion 1988 0.78
61 Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen. Clin Cancer Res 1998 0.78
62 Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer. Cancer Res 1995 0.78
63 Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer. Hum Antibodies Hybridomas 1993 0.77
64 Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region. Cancer Biother Radiopharm 2005 0.77
65 Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model. Clin Cancer Res 1999 0.77
66 Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts. Clin Cancer Res 1999 0.77
67 Adenoviral-mediated delivery of gastrin-releasing peptide receptor results in specific tumor localization of a bombesin analogue in vivo. Clin Cancer Res 1997 0.77
68 Radiometric assay for direct quantitation of rat liver cytochrome P-450b using monoclonal antibodies. Anal Biochem 1985 0.77
69 Amniotic fluid levels of human chorionic gonadotropin and its alpha and beta subunits in second-trimester chromosomally abnormal pregnancies. Prenat Diagn 1992 0.76
70 Further studies on the protein conjugation of hydroxamic acid bifunctional chelating agents: group-specific conjugation at two different loci. Bioconjug Chem 1999 0.76
71 SEREX analysis for tumor antigen identification in a mouse model of adenocarcinoma. Cancer Gene Ther 2000 0.76
72 Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanoma. Clin Nucl Med 1989 0.76
73 Synthesis of N-[tris[2-[[N-(benzyloxy)amino]carbonyl]ethyl]methyl]succinamic acid, trisuccin. Hydroxamic acid derivatives as a new class of bifunctional chelating agents. Bioconjug Chem 1993 0.76
74 Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med 1992 0.76
75 Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy. Cancer Biother Radiopharm 2003 0.75
76 Quality control of radiolabeled monoclonal antibodies. Cancer Biother Radiopharm 2000 0.75
77 Limited sampling models for HA-1A IgM monoclonal antibody. Hum Antibodies Hybridomas 1990 0.75
78 Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials. Cancer Biother Radiopharm 1997 0.75
79 In-111 labeled monoclonal anti-carcinoembryonic antigen antibody (ZCE025) in the immunoscintigraphic imaging of metastatic antigen-producing adenocarcinomas. Clin Nucl Med 1991 0.75
80 Pharmacokinetics of a mouse/human chimeric monoclonal antibody (C-17-1A) in metastatic adenocarcinoma patients. Pharm Res 1990 0.75
81 Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma. J Immunother Emphasis Tumor Immunol 1993 0.75
82 Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: a phase I study. Adv Exp Med Biol 1994 0.75
83 Lack of T-cell immunity in humans with preexisting anti-mouse immunoglobulin reactivity. Cancer Res 1992 0.75
84 Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion protein. Cancer Biother Radiopharm 2005 0.75
85 Cardiac electrophysiologic effects of acute and chronic amiodarone administration in the isolated perfused rabbit heart: altered thyroid hormone metabolism. J Pharmacol Exp Ther 1986 0.75
86 Radioimmunoscintigraphic detection of occult gestational choriocarcinoma. Am J Obstet Gynecol 1987 0.75
87 Selection of monoclonal antibody to hCG which localizes in human choriocarcinoma growing in the Syrian hamster cheek pouch. Hybridoma 1984 0.75
88 Choriocarcinoma: blocking factor and monoclonal antibody iodine 131 imaging. Am J Obstet Gynecol 1984 0.75
89 Sensitization of radiolabeled monoclonal antibody therapy using bromodeoxyuridine. Cancer 1994 0.75
90 Monoclonal antibodies against beta-human chorionic gonadotropin. A comparative immunohistochemical study. Arch Pathol Lab Med 1984 0.75
91 An animal model to predict the immunogenicity of murine V regions in humans. Hum Antibodies Hybridomas 1993 0.75
92 Production of mouse monoclonal anti-idiotypic antibodies specific to epitopes of tumor-associated mucin TAG-12. Hybridoma 1994 0.75
93 Development and characterization of a monoclonal antibody which distinguishes the beta-subunit of human chorionic gonadotropin (beta hCG) in the presence of the hCG. Endocrinology 1981 0.75
94 Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy. Cancer Biother Radiopharm 2003 0.75
95 Isolated ectopic production of the free beta subunit of chorionic gonadotropin by an epidermoid carcinoma of unknown primary site. Cancer 1985 0.75
96 A novel monoclonal antibody design for radioimmunotherapy. Cancer Biother Radiopharm 2003 0.75
97 Changes in cardiac muscle function and biochemistry produced by long-term amiodarone and amiodarone + triiodothyronine administration in the rabbit. Pharmacology 1987 0.75
98 Development and characterization of a monoclonal antibody to human embryonal carcinoma. J Urol 1987 0.75